Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Oropharyngeal Neoplasms 8Urinary Bladder Neoplasms 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 5Endometrial Neoplasms 5Colorectal Neoplasms 5Cholangiocarcinoma 5Carcinoma 5Biliary Tract Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Mouth Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Squamous Cell 4Mesothelioma, Malignant 3Laryngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Triple Negative Breast Neoplasms 2Tongue Neoplasms 2Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Non-squamous Non-small Cell Lung Cancer 2

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Cisplatin × 30 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡